Table 1.

Patient and tumor characteristics

Characteristic	N (%)
Age, years [median (range)]	61.3 (30–97)
Post-menopausal^a	181 (73.6%)
Tumor grade^b
1	103 (33.4%)
2	191 (62.0%)
3	14 (4.6%)
Receptor subtype^c
ER+/PR+/HER2−	216 (78.3%)
ER+/PR−/HER2−	41 (14.9%)
HER2+	14 (5.1%)
Triple negative	5 (1.8%)
Lymphovascular invasion	18 (5.7%)
Presence of lobular carcinoma in situ^d	232 (75.1%)
Tumor multifocality	97 (31.3%)
Pleomorphic ILC	31 (9.9%)
Nodal stage
N0	239 (76.1%)
N1	47 (15.0%)
N2	11 (3.5%)
N3	17 (5.4%)
Tumor stage
T1	194 (61.8%)
T2	96 (30.6%)
T3	24 (7.6%)
Overall stage
1	244 (77.7%)
2	50 (15.9%)
3	20 (6.4%)
Follow-up time, years [median (range)]	4.5 (0.5–26)

Data are expressed as n (%) unless otherwise specified

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2

^aData available in n = 246; ^bdata available in n = 308; ^cdata available in n = 276; ^ddata available in n = 309